12th Cold Chain GDP & Temperature Management Logistics Forum Releases Results of 2014 Industry Investment Survey
July 22, 2014
Survey Gives Insight into Where Senior Executives Are Investing Their Money
The 12th Cold Chain GDP & Temperature Management Logistics Forum recently released an infograph that presents the results of their 2014 industry survey. The survey offers the most current insight into where Senior Level Executives are investing the money for their businesses. The 12th Cold Chain GDP & Temperature Management Logistics Forum will be covering key topics such as this, and much more, throughout the week on September 29-October 3, at the John B. Hynes Convention Center in Boston.
The Global Forum asked a targeted portion of attendees to participate in the survey to share their current investment plans. The top 9 investment priorities of today are compiled into the infograph, with information about the timeframe they plan to make these investments in and the size of the budgets they have to spend as well. Download the infograph here: http://bit.ly/1rkCFae
“The Cold Chain Global Forum prides itself on being the industry’s number one resource, and with that comes the responsibility to provide the industry with the most innovative, up-to-date information,” said Claudia Rubino, Divisional Director for the Americas for IQPC’s Cold Chain Portfolio. “This survey is just a small preview of the information that will be presented at the event in September, and I’m excited to see the industry use key takeaways from this forward-thinking program.”
The event program will feature a variety of sessions including Breakfast Briefings from Vascular Science and National Research Council (NRC) Canada, an interactive site tour of the Cold Chain Technologies Facilities, an International Focus Day highlighting Brazil, China, Russia, Thailand and India, multiple tracks focusing on supply chain integrity, small pharma & biotech supply changes, container qualification and much more.
The impressive speaker faculty on board for the program includes FDA, Pfizer, Eli Lilly, Cardinal Health, AbbVie, Purdue Pharma, Novo Nordisk, Genentech, Bristol Meyers-Squibb, American Red Cross, CDC, CSL Behring, and Luminex Corporation among others